“What we found was [that] every subgroup, whether they were less than or greater than 100 mLs, or whether they had an obstructive median lobe or didn't have a median lobe, [all] showed significant improvements…regardless of their subcategory,” says Dean Elterman, MD, MSc, FRCSC.
Scott T. Tagawa, MD, discusses a study of treatment patterns and overall survival in metastatic castration-sensitive prostate cancer between 2006 and 2019.
Tian Zhang , MD, discusses the adaptive phase 3 PDIGREE study comparing immunotherapy only versus immunotherapy/TKI regimens in patients with advanced kidney cancer.
Jordan J. Kramer, MD, discusses the background and findings of the study, “Statin use and lower urinary tract symptoms (LUTS) incidence and progression in reduction by dutasteride of prostate cancer events (REDUCE) trial.”
“I think the big findings are that men know about testicular cancer, but they may not know a lot and they feel like they could know more,” says Shawn Dason, MD.
“Ideally…we have a technology that's noninvasive that we can use in the clinic, where they don't require any anesthesia to…break the stones and make them smaller,” says Mathew D. Sorensen, MD, MS, FACS.
“Clearly, we are now in that era of TKIs in addition to checkpoint inhibitors, and so…it makes logical sense from the place we're at [in] the moment in renal cancer treatment with those combinations of treatment,” says Grant Stewart, MD.
Julie N. Graff, MD, of OHSU Knight Cancer Institute, comments on the impact of the availability of newer-generation androgen receptor inhibitors on treatment outcomes for patients with advanced prostate cancer.
The role of urologists in working with medical oncologists to treat patients with advanced prostate cancer, with special considerations for early referral.
“My opinion is that the practices that continue to utilize telemedicine moving forward after the pandemic are going to be the leaders in urology,” says Lisa J. Finkelstein, DO.
“The data…showed us that a lot of young [men]…are coming in for ED, and we can't really think of it as just a disease of older men…It can affect you at any age,” says Denise Asafu-Adjei, MD, MPH.
“What stood out for me in prostate cancer is the new imaging opportunities for patients with advanced prostate cancer or prostate cancer recurrence,” says Kelly L. Stratton, MD, FACS.
“This study was very important in that it showed cost savings with MOSES as well as the ability to reliably achieve same-day discharge,” says Matthew S. Lee, MD.
“I think the surgeon voice is an important voice to be heard because there's not a lot of avenues for surgeons to be able to be honest and share all the things they've learned and all the things they've experienced with their patients,” says Una Lee, MD, FPMRS.
GenesisCare doctors Kishore K. Dass, MD, Anurag Agarwal, MD, and Jerry Singer, MD, share their expert insight on the novel PSMA-PET imaging diagnostic Pylarify .
This video features commentary from Leonard Bitterman, the first patient in the United States to receive Pylarify.
“In short, there's a ton of missed opportunity to see how smoking affects treatments, especially in trial patients, and even in our patients that are in our clinics,” says Richard Matulewicz, MD, MS.
Among the highlights will be a talk from Senator Bill Cassidy, MD (R-LA).
As a committee, we felt that there was a need to put together a document to help field some of the ethical considerations that we run into in clinical care but have very little guidance on,” says Anne M. Suskind, MD, MS, FACS, FPMRS.
“One of the study findings that really stood out to me was that so many of the surgeons that we spoke to are…such strong advocates for their patients,” says Wai Lee, MD.
“Even factoring in the increased number of emergency room visits, there was still an overall cost savings of $747 in favor of the Moses HoLEP. So, that was surprising to see,” says Matthew S. Lee, MD.
"The focus of this study and the patient cohort that we're looking at are patients with intermediate-risk bladder cancer who [also have] low-grade bladder cancer. These patients [typically have] a lot of recurrences [and] multi-focal disease but are at low risk of progressing on to metastatic disease or developing invasion into their bladder wall,” says William C. Huang, MD.
“The world's a very, very small place and there are a lot of people who are hurting. It's our job as physicians to help relieve that discomfort, wherever it may exist, whether it's here in the United States or elsewhere, and this is the device that allows that to be realized,” says Ralph V. Clayman, MD.
Michel Pavic, MD, discusses how the combination of masitinib with docetaxel could be a new first-line treatment option for patients with metastatic castration-resistant prostate cancer.
“The concept behind the NAXIVA trial was to treat these patients with pre-surgical neoadjuvant targeted therapy with a means of downstaging that venous tumor thrombus, reducing the extent of it to try and make the surgery less morbid to the patient and to potentially improve survival,” says Grant Stewart, MD.
“It is a vaccine that is self-administered by the patient sublingual over 3 months, and that is why it appears to be so safe,” says J. Curtis Nickel, MD.
“This study really demonstrates, for one of the first times certainly in the largest cohort of men ever [studied], that Rezum water vapor thermal therapy is a viable option to treat men with very large prostates bigger than 80 mL,” says Dean Elterman, MD, MSc, FRCSC.
“I think these results are very encouraging [in] that we may be able to bridge the gap in prostate cancer treatment, in which we're selective [and] prostate gland-sparing,” says Behfar Ehdaie, MD, MPH.
“The take-home message is vibegron is a very safe drug and there are no concerns about any kind of cardiovascular adverse effects,” says Michael A. Weber, MD.
“In general, urologists are really happy people. They love their work, but they're not exempt from the challenges that come with any workplace, especially when you have a lot of different roles, you have a fast environment, and the stakes are high,” says Loren Jean Smith.
